Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations

Cordula M. Wolf, Michael Arad, Ferhaan Ahmad, Atsushi Sanbe, Scott A. Bernstein, Okan Toka, Tetsuo Konno, Gregory Morley, Jeffrey Robbins, J. G. Seidman, Christine E. Seidman, Charles I. Berul*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

BACKGROUND - PRKAG2 mutations cause glycogen-storage cardiomyopathy, ventricular preexcitation, and conduction system degeneration. A genetic approach that utilizes a binary inducible transgenic system was used to investigate the disease mechanism and to assess preventability and reversibility of disease features in a mouse model of glycogen-storage cardiomyopathy. METHODS AND RESULTS - Transgenic (Tg) mice expressing a human N488I PRKAG2 cDNA under control of the tetracycline-repressible α-myosin heavy chain promoter underwent echocardiography, ECG, and in vivo electrophysiology studies. Transgene suppression by tetracycline administration caused a reduction in cardiac glycogen content and was initiated either prenatally (Tg) or at different time points during life (Tg, Tg, and Tg). One group never received tetracycline, expressing transgene throughout life (Tg). Tg mice developed cardiac hypertrophy followed by dilatation, ventricular preexcitation involving multiple accessory pathways, and conduction system disease, including sinus and atrioventricular node dysfunction. CONCLUSIONS - Using an externally modifiable transgenic system, cardiomyopathy, cardiac dysfunction, and electrophysiological disorders were demonstrated to be reversible processes in PRKAG2 disease. Transgene suppression during early postnatal development prevented the development of accessory electrical pathways but not cardiomyopathy or conduction system degeneration. Taken together, these data provide insight into mechanisms of cardiac PRKAG2 disease and suggest that glycogen-storage cardiomyopathy can be modulated by lowering glycogen content in the heart.

Original languageEnglish
Pages (from-to)144-154
Number of pages11
JournalCirculation
Volume117
Issue number2
DOIs
StatePublished - Jan 2008

Funding

FundersFunder number
National Heart, Lung, and Blood InstituteR01HL076751

    Keywords

    • Cardiomyopathy
    • Electrophysiology
    • Genes
    • Glycoproteins
    • Wolff-Parkinson-White syndrome

    Fingerprint

    Dive into the research topics of 'Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations'. Together they form a unique fingerprint.

    Cite this